CRF (R153) polyclonal antibody

Product Specifications

Background

Individuals suffering from Alzheimer’s disease (AD) exhibit dramatic reductions in the content of corticotropin-releasing factor (CRF), increased expression of CRF receptors (CRFRs) and abnormalities in neuronal morphology in affected brain areas. In addition, AD patients show decreased concentrations of CRF in their cerebrospinal fluid, which may contribute to their cognitive impairment. A high affinity CRF binding protein, designated CRF-BP, has been discovered in post-mortem brain samples from AD patients. CRF-BP serves to bind and inactivate CRF, reducing the pool of “free CRF” available to bind CRFRs. Two CRFRs, designated CRF-RI and CFR-RII, have been described and exhibit distinct brain localizations.

CAS Number

9007-83-4

Structure Composition

Rabbit IgG, 1mg/ml in PBS with 0.02% sodium azide, 50% glycerol, pH7.2

Product Name Alternative

Corticoliberin; Corticotropin-releasing factor; CRF; Corticotropin-releasing hormone; CRH

Swiss Prot

P06850

Reactivity

Human, Mouse, Rat

Immunogen

Synthetic peptide, corresponding to amino acids 121-170 of Human CRF.

Conjugation

Unconjugated

Applications

IHC

Dilution

IHC: 1:50~1:200

Purity

The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE) .